Sudarshan Pharma Industries Limited (SPIL) has announced its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025, revealing significant developments and strategic moves that underscore the company's growth trajectory.

Financial Performance

SPIL reported robust financial results for the quarter ended September 30, 2025. The company's consolidated revenue stood at ₹17,573.21 crore, with a net profit after tax of ₹544.61 crore for the quarter. These figures demonstrate the company's strong market position and operational efficiency.

Strategic Acquisitions and Expansions

SPIL has made significant strides in expanding its global footprint and manufacturing capabilities:

Dubai Court Award

The company received ₹2.01 crore from a Dubai Court award against Regans International DMCC and Nand Biharilal Chhabaria, with additional amounts pending.

Acquisition in Dubai

On August 5, 2025, SPIL acquired a 100% stake in Cibachem General Trading LLC, Dubai, for ₹55.00 lakhs, marking its entry into the UAE market.

Manufacturing Facility Acquisition

SPIL entered a definitive agreement to acquire an operational manufacturing facility in Telangana from Srigen Lifesciences for ₹25.50 crores, bolstering its production capabilities.

Fund Raising and Financial Strategies

The Board of Directors has approved ambitious fund-raising plans:

• Approval to raise funds up to ₹1,500.00 crores through various securities.
• BSE granted in-principle approval for FCCB issuance up to USD 35 million on September 16, 2025.

Accounting Standards Transition

In a move towards greater financial transparency, SPIL has voluntarily adopted Indian Accounting Standards (Ind AS) with a transition date of April 1, 2024.

Financial Highlights

Outlook

These strategic moves and strong financial performance position Sudarshan Pharma Industries Limited for continued growth in the pharmaceutical and chemical sectors. The company's focus on expanding its manufacturing capabilities and global presence, coupled with its robust financial strategies, indicates a positive outlook for the future.

Sudarshan Pharma Industries Limited (SPIL) has made significant strides in its expansion plans, securing approval for project relocation and strategically investing in an operational API facility. These developments mark important milestones in the company's growth strategy.

Project Relocation and Timeline Extension

Sudarshan Pharma has obtained approval to relocate its Vitamin B6 and B1 greenfield projects from MIDC, Maharashtra to GIDC, Gujarat. The company cited local resistance issues at the original location as the reason for the change. Along with the relocation approval, the Department of Pharmaceuticals has extended the Scheme Commencement of Production (SCOP) timeline to December 31, 2027.

This extension provides Sudarshan Pharma with additional time to set up its greenfield projects for Vitamin B6 and Vitamin B1 production. The company had initially requested an extension until June 30, 2026, for using existing units in GIDC, or until December 31, 2027, for setting up fresh projects on new land.

Strategic Investment in API Facility

In a separate development, Sudarshan Pharma has announced a significant strategic investment to boost its manufacturing capacity. The company has signed a definitive agreement with Srigen Lifesciences Private Limited for the transfer of capital assets, including land, building, and plant & machinery, at a fully operational manufacturing facility in Telangana.

Key points of the investment include:

• Investment Value: Rs. 25.50 crore
• Location: Strategic location in Telangana - 501401
• Capacity Enhancement: The facility adds instant production capacity, accelerating supply chain responsiveness and overall throughput.
• Product Portfolio Expansion: The acquired facility is capable of producing complex, high-margin molecules, enhancing SPIL's offerings in global therapeutic markets.

Strategic Benefits

The investment in the operational API facility is expected to yield several strategic benefits for Sudarshan Pharma:

1. Immediate Manufacturing Scale-Up: The acquisition provides instant production capacity, improving supply chain responsiveness.
2. Faster Time-to-Market: With existing infrastructure and regulatory frameworks, SPIL can significantly reduce product launch timelines.
3. Expanded Product Portfolio: The facility enables production of high-value, technically complex pharmaceutical ingredients.
4. Regulatory Advantage: The facility's proven compliance track record is expected to shorten approval cycles and lower regulatory costs.

Executive Commentary

Sachin Mehta, Joint Managing Director & Chief Financial Officer of SPIL, commented on the investment: "This investment represents a pivotal milestone in Sudarshan Pharma's growth agenda. It not only strengthens our manufacturing backbone but also significantly enhances our ability to serve global markets with agility, quality, and regulatory compliance. This addition is expected to contribute meaningfully to both revenue and profitability, supporting our financial performance and long-term shareholder value creation."

These developments demonstrate Sudarshan Pharma's commitment to expanding its manufacturing capabilities and strengthening its position in the pharmaceutical and specialty chemicals sectors. The company's focus on vertical integration, operational efficiency, and product diversification is likely to drive its growth in both domestic and global markets.